Clinical trials: Tumor Gastric
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
- Trial name
- NCT06560528
- Testing
- combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer Stage III
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with…
- Trial name
- NCT06939439
- Testing
- Tislelizumab + SOX Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 416 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer, Cervical Cancer
Bupropion in Helping Adults Stop Smoking
RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00534001
- Testing
- bupropion hydrochloride
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Roswell Park Cancer Institute
Stomach Neoplasms
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer
Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1 and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks.
- Trial name
- TIROX2 (NCT00512681)
- Testing
- Irinotecan, Oxaliplatin, TS-1
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- National Cancer Center, Korea
T1 Gastric Cancer Lymph Node Metastasis Early Gastric Cancer Artificial Intelligence-Assisted Diagnosis Multimodal Data Integration
Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
This study aims to develop and validate an artificial intelligence (AI) model that integrates clinical, pathological, and imaging data to predict the presence of lymph node metastasis (LNM) in patients with T1-stage gastric…
- Trial name
- NCT07124754
- Testing
- Multimodal Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in T1 Gastric Cancer
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qun Zhao
Gastric Cancer
The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using Single-site for Surgical Treatment of Early Gastric Cancer
Gastric cancer is one of the most common malignancy worldwide. Surgical resection of the tumor is the only curative treatment for gastric cancer.
- Trial name
- NCT02347956
- Testing
- Reduced port robotic distal gastrectomy
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Yonsei University
Gastric Cancer, Chemotherapy
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
To evaluate the efficacy and safety of Sintilimab combined with apatinib and chemotherapy as First-line or second-line Therapy in Treatment of HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer.
- Conditions
- Gastric Cancer, Chemotherapy, Immunotherapy
- Trial name
- NCT05216237
- Testing
- Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Jiuda Zhao
Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
- Trial name
- NCT06921837
- Testing
- BDC-4182
- Where
- 16 sites in Australia, South Korea and 1 more
- Volunteers
- 122 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma
To evaluate the clinical efficacy of perioperative treatment with S-1 + oxaliplatin (SOX)+ HLX10 compared with SOX as the control in patients with cT3-4N1-3M0 PD-L1-positive (CPS ≥ 5) locally advanced gastric adenocarcinoma or…
- Trial name
- PLATANUS (NCT07699939)
- Testing
- serplulimab
- Where
- 18 sites in Japan, South Korea
- Volunteers
- 136 people
- Sponsor
- National Cancer Center, Japan
Gastro-esophageal Reflux
Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy
The purpose of this research study is to measure acid reflux into the throat both before and after medical treatment in people who have had radiation therapy to their head and neck for the treatment of cancer.
- Trial name
- NCT00222079
- Testing
- Esomeprazole (Nexium)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Douglas Trask
Advanced Solid Tumours
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment…
- Trial name
- NCT01163903
- Testing
- pantoprazole sodium for injection, doxorubicin hydrochloride injection
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Esophagogastroduodenoscopy
AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal Tract
The purpose of our study was to assess the performance of esophagogastroduodenoscopy automatic quality-control system in real-time quality control of EGD.
- Trial name
- NCT04720924
- Testing
- Computer-aided Real-time Automatic Quality-control System
- Where
- 6 sites in China
- Volunteers
- 1,840 people
- Sponsor
- Shandong University
Stomach Neoplasms
S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
This study is an open-label, single-center, and randomized phase II study designed to evaluate each efficacy and safety of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic…
- Trial name
- NCT00580359
- Testing
- S-1, capecitabine
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- National Cancer Center, Korea
Gastric Neoplasm
The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
Endoscopic submucosal dissection (ESD) is an effective treatment for early gastric cancer or premalignant lesions in the stomach.
- Trial name
- NCT02235246
- Testing
- Magnesium Sulfate, Normal saline
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Gastrointestinal Cancer, Colon Cancer
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder…
- Conditions
- Gastrointestinal Cancer, Colon Cancer, Rectal Cancer, Anal Cancer
- Trial name
- NCT06263088
- Testing
- EQUITY GI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Cancer
Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial
The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls.
- Trial name
- NCT01341756
- Testing
- Palliative Radiotherapy
- Where
- Singapore
- Volunteers
- 63 people
- Sponsor
- National University Hospital, Singapore
Advanced Gastric Cancer
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Because well-designed, randomized, controlled clinical trials are lacking in patients with advanced gastric cancer (AGC), and because randomly allocating patients to treatments that do not accord with their preferences may…
- Trial name
- NCT00821990
- Testing
- Chemotherapy, Best supportive care
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Stage IV Colorectal Cancer, Gastric Cancer
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
The purpose of this study is to investigate the association between UGT1A1 polymorphisms and neutropenia and diarrhea in Korean patients with advanced colorectal or gastric cancer treated with FOLFIRI regimen.
- Trial name
- NCT01271582
- Testing
- Irinotecan, 5FU, leucovorin
- Where
- 5 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer
Background: It is shown that TS-1 as adjuvant chemotherapy after D2 resection in patients with gastric cancer can improve DFS and OS in one Japanese Trial. And TS-1 has become one of the standard therapies to these patients.
- Trial name
- CAPITAL (NCT01795027)
- Testing
- S-1 plus oxaliplatin, S-1 single
- Where
- 13 sites in China
- Volunteers
- 724 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.